SLC5A2 and type 2 diabetes mellitus: Sano et al. reported increased grip strength in male and female T2DM patients treated with the SGLT2 inhibitor empagliflozin, whereas a meta-analysis by Pan et al. reported that these drugs reduce skeletal muscle mass [104,105].